The financials
UroGen Pharma Ltd. by the numbers
UroGen Pharma Ltd. (URGN) reported revenue of $51M in Q1 2026 (quarter ended Mar 31, 2026), up 152% from the same quarter a year earlier. That came with a gross margin of 92% and net loss of $24M. For the full year FY2025, revenue was $110M (+21% year on year) and net income −$153M. Its largest product in Jun 2026 was Zusduri at $50M, 70% of the disclosed total, well ahead of Jelmyto at 30%.
| Income statement | Q1 2026 | Q1 2025 | Change |
|---|---|---|---|
| Revenue | $51M | $20M | +152% |
| Gross profit | $47M | $18M | +161% |
| Operating income | −$20M | −$37M | n/a |
| Net income | −$24M | −$44M | n/a |
| Product | Revenue | Share |
|---|---|---|
| Zusduri | $50M | 70% |
| Jelmyto | $22M | 30% |
Business Segments
Revenue split by product segment, from SEC XBRL filings.
Latest period: Jun 2026Total $72.5M (+42%)
Jelmyto grew -9.0% year on year
Segment Latestquarter on quarteryear on year
- Zusduri$50.4M$50.4MQoQ +72%year on year -+72%-
- Jelmyto$22.0M$22.0MQoQ +1.5%year on year -9.0%+1.5%-9.0%